Table 2.
Symptom and Gaze Behavior Measures Pre- vs. Post-treatment in GSAD Group Completers (n=15)1
| Week 0 Mean (SD) |
Week 8 Mean (SD) |
T | df | P | |
|---|---|---|---|---|---|
| LSAS | 82.6 (15.5) | 45.9 (25.6) | 5.9 | 14 | <0.001 |
| GARS | 51.2 (15.7) | 29.6 (14.5) | 5.3 | 14 | <0.001 |
| HRSD-17 | 6.3 (3.3) | 3.9 (3.5) | 1.9 | 14 | 0.076 |
| % fixations on eye region, direct stimuli |
60.0 (23.4) | 39.2 (27.4) | 4.8 | 11 | <0.001 |
| % fixations on eye region, averted stimuli |
60.8 (20.9) | 40.9 (25.2) | 4.0 | 11 | 0.002 |
| % fixations on eye region, direct – averted |
−0.8 (7.7) | −1.6 (8.4) | 0.3 | 11 | 0.76 |
| Scanpath length (pixels), direct stimuli |
3154.0 (1077.1) | 4063.3 (1747.1) | 1.3 | 11 | 0.22 |
| Scanpath length (pixels), averted stimuli |
2842.2 (1167.8) | 4191.1 (2050.0) | 1.7 | 11 | 0.11 |
| Scanpath length (pixels), direct – averted |
311.8 (491.1) | −127.9 (945.2) | 1.5 | 11 | 0.17 |
LSAS = Liebowitz Social Anxiety Scale; GARS = Gaze Aversion Rating Scale; HRSD-17 = Hamilton Rating Scale for Depression, 17-Item Version
1
Eye gaze data for 3 patients were excluded from analysis due to technical problems with acquisition.